Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Average Target Price from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have earned an average rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $7.00.

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Precigen in a research report on Friday, November 15th.

Precigen Price Performance

NASDAQ:PGEN opened at $0.73 on Thursday. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93. The business has a 50 day simple moving average of $0.83 and a 200 day simple moving average of $1.11. The firm has a market capitalization of $212.71 million, a P/E ratio of -1.32 and a beta of 1.71.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in Precigen by 4.8% in the second quarter. Bank of New York Mellon Corp now owns 421,788 shares of the biotechnology company’s stock worth $666,000 after purchasing an additional 19,301 shares during the period. ClariVest Asset Management LLC boosted its holdings in shares of Precigen by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 13,752 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Precigen by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after acquiring an additional 130,500 shares in the last quarter. AQR Capital Management LLC raised its holdings in Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 18,097 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Precigen by 40.7% in the second quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 16,486 shares during the period. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.